Abivax reported its financial results for the first half of 2026, characterized by a significant increase in operational investment as the company advances its lead candidate, obefazimod, toward a planned New Drug Application (NDA) submission in late 2026. While the net loss widened due to increased R&D and pre-commercialization activities, the company significantly de-risked its balance sheet by repurchasing all outstanding royalty certificates and securing a massive capital infusion in July, extending its financial viability for several years.
Key Highlights
- R&D expenses increased 38% year-over-year to €107.9 million, primarily driven by Phase 3 maintenance trials for obefazimod in ulcerative colitis and progressing Phase 2b trials in Crohn’s disease.
- The company reported a net loss of €165.9 million for the first half of 2026, compared to a loss of €100.8 million in the first half of 2025.
- Pro-forma cash resources, including €767.1 million in net proceeds from a July 2026 public offering, provide a projected cash runway into the fourth quarter of 2029.